Lacto-N-biose (LNB) has the value and potential for physiological function research and food market application. In this regard, CD BioGlyco accumulates many years of scientific research experience and provides you with high-quality services for LNB production.
LNB is a disaccharide that plays an important role in the carbohydrate structure of several glycoconjugates. The compound exists in HMO, but cannot exist in the form of free disaccharides, and has acted as the structural unit of type I oligosaccharide with lacto-N-tetrasaccharide as the core structure. Oligosaccharides type I is only found in animals such as milk and monkeys, while oligosaccharides type II is found in mammalian milk. In addition, LNB glycans are present in the glycolipid and glycoprotein domains of several cell types, including intestinal epithelial cells and blood group antigens.
Fig.1 Lacto-N-biose I. (Kiyat, et al., 2020)
Probiotics are living microorganisms that have beneficial effects on host health at appropriate doses. Bifidobacterium, a genus of Gram-positive anaerobic bacteria, is a well-known probiotic and one of the major commensal microbiota in the gut of healthy humans and animals. Nondigestible food ingredients that promote probiotics’ growth and/or activity are called prebiotics. Bifidobacteria predominated in the gut of breastfed infants, but not formula-fed infants, suggesting a prebiotic component of Bifidobacteria in breast milk. A large number of bifidofactors in breast milk consist of oligosaccharides. Human milk oligosaccharides are a good carbon source for the efficient growth of several strains of bifidobacteria. Studies have shown that LNB is a highly specific natural prebiotic for Bifidobacteria. It is the first time for newborn infants to obtain it from their mother's colostrum. It can be used by many Bifidobacterium strains, including 208 strains of 10 species and 4 subspecies.
CD BioGlyco has accumulated a variety of Production Solutions to meet changing client needs. To achieve efficient production of LNB, our technology has been optimized in many aspects, including but not limited to the following:
Selection and identification of suitable enzymes.
Using a bioreactor system with immobilized enzymes.
A complete and mature service product line from strain development to mass manufacturing.
Inhibiting or increasing the expression of genes necessary for homologous or heterologous pathway balance in strains to reduce the impact on cell growth.
The selection of enzymes such as sucrose phosphorylase and transglycosidase depends on different synthetic methods and microbial resources including Xanthomonas manihotis, Bifidobacterium bifidum, Xanthomonas manihotis, and Bifidobacterium bifidum.
CD BioGlyco has a variety of synthetic routes for LNB to meet your needs. If you have any further queries, please contact us directly for more detailed information.
Reference
